Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 3/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819579 | 0.88 | HTR2C (0.54) | HTR2CHTR2AHTR2BTACR1HTR1A | |
| SCHEMBL1819576 | 0.88 | HTR2C (0.54) | HTR2CHTR2AHTR2BTACR1HTR1A | |
| SCHEMBL29350958 | 0.88 | HTR2C (0.54) | HTR2CHTR2AHTR2BTACR1HTR1A | |
| SCHEMBL1819580 | 0.88 | HTR2C (0.54) | HTR2CHTR2AHTR2BTACR1HTR1A | |
| Bicarbonate SCHEMBL7446322 | 0.85 | HTR2C (0.55) | HTR2CHTR2AHTR2BTACR1HTR1A | |
| SCHEMBL7099439 | 0.84 | HTR2C (0.50) | HTR2CTACR1AKT1 | |
| SCHEMBL17474574 | 0.83 | RPS6KB1 (0.45) | AKT1RPS6KB1 | |
| SCHEMBL17485184 | 0.83 | MAPT (0.56) | HTR2CHTR2AHTR2BTACR1HTR1A | |
| SCHEMBL17486613 | 0.83 | MAPT (0.56) | HTR2CHTR2AHTR2BTACR1HTR1A | |
| SCHEMBL15054700 | 0.82 | AKT1 (0.56) | HTR2CHTR2AHTR2BHTR1AAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3174864-A2 | VMAT INHIBITORY COMPOUNDS | Oregon Health & Science University (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9546151-B2 | VMAT inhibitory compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2016-02-04 | — | — | US | disclosed |
| WO-2016019312-A2 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | HTR2C 83/4885HTR2A 55/4885HTR2B 100/4885 |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | HTR2C 83/4885HTR2A 55/4885HTR2B 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.